Grant: Master's Award: Canada Graduate Scholarships
University of Calgary
$17,500.00
Combination treatment of Indapamide and Hydroxychloroquine to attenuate neurodegeneration in an animal model of MS
EF 2018-19
Résumé
Multiple Sclerosis (MS), affecting roughly 2.5% of Canadians, is a chronic inflammatory disease where immune cells attack the central nervous system leading to damaged areas called lesions. These lesions are partly caused by the release of toxic molecules called free-radicals (FRs) that cause nerve cell death and neurological impairments. There are multiple forms of the disease, however a progressive form called primary progressive MS (PPMS) is more likely to occur in older individuals. PPMS currently lacks effective treatment options and any drugs available are insufficient and are at a high cost. Therefore, the present study seeks to unveil an effective and affordable treatment for the aging PPMS population. We will investigate two inexpensive generic drugs: Indapamide, a high blood pressure medication and neutralizer of FRs, and Hydroxychloroquine (HCQ), an anti-malarial drug known to inhibit microglia, an immune cell of which increased activation is a hallmark of PPMS. Over-activation of microglia results in the degradation of myelin, an insulator surrounding nerve cells, along with myelin-producing cells. This breakdown releases molecules contributing to FR formation, thus enhancing the risk of disease progression, especially in older patients. Using an animal model of MS, called EAE, we will observe the effects that the combination of these drugs has on symptom severity, neurodegeneration and inflammation. With HCQ currently in a Phase 2 clinical trial for PPMS and indapamide showing promising effects on FRs in animals, there is optimism that in combination, the drugs will have strong therapeutic potential targeting multiple aspects of the disease. This will give rise to a new treatment plan to fill the void that currently exists for PPMS.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
406536
Name
Brown Dennis I
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Combination treatment of Indapamide and Hydroxychloroquine to attenuate neurodegeneration in an animal model of MS
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Aging; Demyelination; Experimental Autoimmune Encephalomyelitis; Lymphocytes; Macrophage; Microglia; Multiple Sclerosis; Neurodegeneration; Neuroimmunology; Oxidative Stress
Abstract
Multiple Sclerosis (MS), affecting roughly 2.5% of Canadians, is a chronic inflammatory disease where immune cells attack the central nervous system leading to damaged areas called lesions. These lesions are partly caused by the release of toxic molecules called free-radicals (FRs) that cause nerve cell death and neurological impairments. There are multiple forms of the disease, however a progressive form called primary progressive MS (PPMS) is more likely to occur in older individuals. PPMS currently lacks effective treatment options and any drugs available are insufficient and are at a high cost. Therefore, the present study seeks to unveil an effective and affordable treatment for the aging PPMS population. We will investigate two inexpensive generic drugs: Indapamide, a high blood pressure medication and neutralizer of FRs, and Hydroxychloroquine (HCQ), an anti-malarial drug known to inhibit microglia, an immune cell of which increased activation is a hallmark of PPMS. Over-activation of microglia results in the degradation of myelin, an insulator surrounding nerve cells, along with myelin-producing cells. This breakdown releases molecules contributing to FR formation, thus enhancing the risk of disease progression, especially in older patients. Using an animal model of MS, called EAE, we will observe the effects that the combination of these drugs has on symptom severity, neurodegeneration and inflammation. With HCQ currently in a Phase 2 clinical trial for PPMS and indapamide showing promising effects on FRs in animals, there is optimism that in combination, the drugs will have strong therapeutic potential targeting multiple aspects of the disease. This will give rise to a new treatment plan to fill the void that currently exists for PPMS.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Brown, Dennis I
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~